Literature DB >> 17979772

SPR-based fragment screening: advantages and applications.

T Neumann1, H-D Junker, K Schmidt, R Sekul.   

Abstract

Fragment-based screening has recently evolved into a promising strategy in drug discovery, and a range of biophysical methods can be employed for fragment library screening. Relevant approaches, such as X-ray, NMR and tethering are briefly introduced focussing on their suitability for fragment-based drug discovery. In particular the application of surface plasmon resonance (SPR) techniques to the primary screening of large libraries comprising small molecules is discussed in detail. SPR is known to be a powerful tool for studying biomolecular interactions in a sensitive and label-free detection format. Advantages of SPR methods over more traditional assay formats are discussed and the application of available channel and array based SPR systems to biosensing are reviewed. Today, SPR protocols have been applied to secondary screening of compound libraries and hit conformation, but primary screening of large fragment libraries for drug discovery is often hampered by the throughput of available systems. Chemical microarrays, in combination with SPR imaging, can simultaneously generate affinity data for protein targets with up to 9,216 immobilized fragments per array. This approach has proven to be suitable for screening fragment libraries of up to 110,000 compounds in a high throughput fashion. The design of fragment libraries and appropriate immobilization chemistries are discussed, as well as suitable follow-up strategies for fragment hit optimization. Finally, described case studies demonstrate the successful identification of selective low molecular weight inhibitors for pharmacologically relevant drug targets through the SPR screening of fragment libraries.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17979772     DOI: 10.2174/156802607782341073

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  40 in total

1.  Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge.

Authors:  Ashutosh Kumar; Kam Y J Zhang
Journal:  J Comput Aided Mol Des       Date:  2012-01-15       Impact factor: 3.686

2.  Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces.

Authors:  Brandon S Zerbe; David R Hall; Sandor Vajda; Adrian Whitty; Dima Kozakov
Journal:  J Chem Inf Model       Date:  2012-07-24       Impact factor: 4.956

Review 3.  Adenylating enzymes in Mycobacterium tuberculosis as drug targets.

Authors:  Benjamin P Duckworth; Kathryn M Nelson; Courtney C Aldrich
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

4.  The multiple roles of computational chemistry in fragment-based drug design.

Authors:  Richard Law; Oliver Barker; John J Barker; Thomas Hesterkamp; Robert Godemann; Ole Andersen; Tara Fryatt; Steve Courtney; Dave Hallett; Mark Whittaker
Journal:  J Comput Aided Mol Des       Date:  2009-06-17       Impact factor: 3.686

5.  Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics.

Authors:  Wan F Lau; Jane M Withka; David Hepworth; Thomas V Magee; Yuhua J Du; Gregory A Bakken; Michael D Miller; Zachary S Hendsch; Venkataraman Thanabal; Steve A Kolodziej; Li Xing; Qiyue Hu; Lakshmi S Narasimhan; Robert Love; Maura E Charlton; Samantha Hughes; Willem P van Hoorn; James E Mills
Journal:  J Comput Aided Mol Des       Date:  2011-05-21       Impact factor: 3.686

Review 6.  Evolutions in fragment-based drug design: the deconstruction-reconstruction approach.

Authors:  Haijun Chen; Xiaobin Zhou; Ailan Wang; Yunquan Zheng; Yu Gao; Jia Zhou
Journal:  Drug Discov Today       Date:  2014-09-27       Impact factor: 7.851

7.  Fragment screening by surface plasmon resonance.

Authors:  Iva Navratilova; Andrew L Hopkins
Journal:  ACS Med Chem Lett       Date:  2010-02-04       Impact factor: 4.345

8.  Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.

Authors:  Douglas R Davies; Bjorn Mamat; Olafur T Magnusson; Jeff Christensen; Magnus H Haraldsson; Rama Mishra; Brian Pease; Erik Hansen; Jasbir Singh; David Zembower; Hidong Kim; Alex S Kiselyov; Alex B Burgin; Mark E Gurney; Lance J Stewart
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

Review 9.  The role of medical structural genomics in discovering new drugs for infectious diseases.

Authors:  Wesley C Van Voorhis; Wim G J Hol; Peter J Myler; Lance J Stewart
Journal:  PLoS Comput Biol       Date:  2009-10-26       Impact factor: 4.475

Review 10.  HTS and hit finding in academia--from chemical genomics to drug discovery.

Authors:  Julie A Frearson; Iain T Collie
Journal:  Drug Discov Today       Date:  2009-09-28       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.